Observed and Predicted Risk of Breast Cancer Death in Randomized Trials on Breast Cancer Screening |
| |
Authors: | Philippe Autier Mathieu Boniol Michel Smans Richard Sullivan Peter Boyle |
| |
Affiliation: | 1Strathclyde Institute of Global Public Health at iPRI, Lyon, France;2International Prevention Research Institute (iPRI), Lyon, France;3Institute of Cancer Policy, Kings Health Partners Cancer Centre, Bermondsey Wing, Guy’s Campus, London, United Kingdom;University of North Carolina School of Medicine, UNITED STATES |
| |
Abstract: | BackgroundThe role of breast screening in breast cancer mortality declines is debated. Screening impacts cancer mortality through decreasing the number of advanced cancers with poor diagnosis, while cancer treatment works through decreasing the case-fatality rate. Hence, reductions in cancer death rates thanks to screening should directly reflect reductions in advanced cancer rates. We verified whether in breast screening trials, the observed reductions in the risk of breast cancer death could be predicted from reductions of advanced breast cancer rates.ResultsThe observed and predicted RR of breast cancer death were 0.72 (0.56–0.94) and 0.98 (0.77–1.24) in the HIP trial, and 0.79 (0.78–1.01) and 0.90 (0.80–1.01) in the Age trial. In the TCT, the observed RR was 0.73 (0.62–0.87), while the predicted RR was 0.89 (0.75–1.05) if overdiagnosis was assumed to be negligible and 0.83 (0.70–0.97) if extra cancers were excluded.ConclusionsIn breast screening trials, factors other than screening have contributed to reductions in the risk of breast cancer death most probably by reducing the fatality of advanced cancers in screening groups. These factors were the better management of breast cancer patients and the underreporting of breast cancer as the underlying cause of death. Breast screening trials should publish stage-specific fatalities observed in each group. |
| |
Keywords: | |
|
|